Yun Karen M, Bazhenova Lyudmila
Division of Hematology-Oncology, Moores Cancer Center at UC San Diego Health, La Jolla, California, USA
Division of Hematology-Oncology, Moores Cancer Center at UC San Diego Health, La Jolla, California, USA.
BMJ Case Rep. 2023 May 8;16(5):e253260. doi: 10.1136/bcr-2022-253260.
Human epidermal growth factor receptor 2 (HER2) alterations can occur as gene mutations, gene amplification or protein overexpression. DESTINY-Lung01 and DESTINY-Lung02 demonstrated the efficacy of trastuzumab deruxtecan in the subsequent line setting in patients with unresectable or metastatic -mutated non-small-cell lung cancer (NSCLC). Trastuzumab deruxtecan has not been studied in select patients with -amplified NSCLC. Here, we present the first reported case of metastatic -amplified NSCLC treated with trastuzumab deruxtecan with a durable response to therapy.
人表皮生长因子受体2（HER2）改变可表现为基因突变、基因扩增或蛋白过表达。DESTINY-Lung01和DESTINY-Lung02试验证明了曲妥珠单抗德鲁昔康在不可切除或转移性HER2突变非小细胞肺癌（NSCLC）患者后续治疗中的疗效。曲妥珠单抗德鲁昔康尚未在特定的HER2扩增NSCLC患者中进行研究。在此，我们报告首例接受曲妥珠单抗德鲁昔康治疗且对治疗有持久反应的转移性HER2扩增NSCLC病例。
